Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04533269 |
Other study ID # |
CI-B001 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
July 31, 2021 |
Est. completion date |
November 30, 2022 |
Study information
Verified date |
November 2020 |
Source |
Cearna, Inc. |
Contact |
Jacqueline Blem |
Phone |
858-945-6456 |
Email |
jacqui[@]cardiffclinical.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Subjects will have a bruise induced. A pad containing either a placebo or active will be
applied to the bruise. Photographs will be taken over the following days to record bruise
healing.
Description:
This is a randomized, double-blind, placebo-controlled, crossover, multicenter study that
will be used to evaluate the difference in bruise reduction efficacy between active remedy
and placebo when a mechanical bruise is induced. The trial will be conducted at 5-8 sites
with up to 150 subjects. Each subject will be injured two times using the same
bruise-inducing mechanism, and the resulting bruises will be treated with active remedy or
placebo-infused pads that will be identical in appearance. Subjects and study investigators
will be blinded to the order of treatment assignment. Subjects will be asked to come to the
clinic for photographic assessments of the bruise. Each subject will be randomly assigned to
have a placebo or active remedy pad applied over each mechanically induced bruise on Day 1.
The pad will be applied by study staff immediately after bruise induction (within 5 minutes).
The pad will cover the bruised area completely, and then sealed with Tegaderm. All
procedures, including bruise induction, treatment, and photography, will be administered by
study staff who are blinded to treatment type. All photographs will be rated according to
standardized criteria by blinded, trained study investigators after the completion of all
subject data collection.